What Management Said
Read the full Q2 2025 transcript ↗Still, same-facility net revenues in our acute care hospital segment increased by 5.7% during the second quarter of 2025 as compared to last year's second quarter after excluding the impact of our insurance subsidiary. For the second quarter of 2025, our solid acute care revenues combined with effective expense controls resulted in a 10% increase in same-facility EBITDA. The new hospitals in Las Vegas and the District of Columbia contributed $35 million to the receivable increase. During the first half of 2025, we also acquired 1.9 million of our own shares at a total cost of approximately $332 million.
Our current projected 2025 full-year net benefit from previously approved state Medicaid supplemental programs is approximately $1.2 billion. Based primarily on the increased DPP reimbursement, we are increasing our midpoint of our 2025 EPS guidance by 7% to $20.50 per diluted share, up from $19.20 per diluted share previously. Medicaid supplemental programs in Washington, D.C., and other potential programs that are not yet fully approved are not included in our revised guidance. We remain pleased with the performance of West Henderson Hospital, which produced a positive EBITDA in the second quarter.
Timing of hospital certification and other startup issues proved a bit more challenging than we anticipated, but demand, especially for emergency services, has been very encouraging. In the table towards the back of the press release, we disclosed year-over-year growth in ADC. A number of the insurance companies, as they've been talking about their increase in Medical Loss Ratios, have pointed to the increase in spending on behavioral care. While they do not provide this level of detail, we believe that a significant chunk of that increase is in outpatient.
What went well
- The company raised the midpoint of its 2025 adjusted EPS guidance by 7% to $20.50 from $19.20, based primarily on increased DPP reimbursement, and reported adjusted net income of $5.35 per diluted share for the quarter.
- Acute care same-facility adjusted admissions increased 2.0% and same-facility net revenues rose 5.7% (excluding the insurance subsidiary), producing a 10% increase in same-facility acute EBITDA on effective expense control.
- West Henderson Hospital produced positive EBITDA in the second quarter, ahead of typical startup expectations.
- Behavioral health same-facility net revenues increased 5.4% excluding the Tennessee DPP, with revenue per adjusted day up 4.2% and adjusted patient days up 1.2%, and adjusted patient days grew faster than unadjusted days, indicating outpatient outgrew inpatient.
- Behavioral de novo growth continued with a 96-bed Grand Rapids, Michigan joint venture and a 41-bed Mount Pleasant, South Carolina center opened, plus Bethlehem, Pennsylvania (144 beds) and Independence, Missouri (120 beds) in development.
- The Cygnet Behavioral Health Network in the U.K. added six new facilities and 137 beds so far in the year, and roughly $185 million of new DPP revenues were incorporated into the ~$1.2 billion full-year supplemental benefit.
- The company repurchased 1.9 million shares for about $332 million in the first half, having bought back approximately 34% of outstanding shares since 2019, with buybacks expected to be elevated as free cash flow rises.
What went wrong
- Cash generated from operating activities fell $167 million to $909 million in the first half, driven by the $58 million Tennessee directed payment receivable and a $35 million receivable increase from the new Las Vegas and D.C. hospitals.
- Cedar Hill Regional Medical Center created a $25 million EBITDA drag in the second quarter, with another $25 million drag embedded for the back half, as Medicare certification took longer than anticipated.
- Acute care surgical volumes were down slightly year over year in the quarter.
- Behavioral volumes continued to fall short of the targeted range, prompting management to scale back back-half behavioral projections.
- Nevada and Las Vegas volumes slowed modestly amid broader economic softness in the market.
- Management outlined a worst-case OB3 Medicaid reduction of approximately $360 million-$400 million by 2032, roughly 60% behavioral and 40% acute.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Adjusted EPS (FY2025) | Full year 2025 | $20.50 midpoint (up 7%) |
| Medicaid supplemental payments net benefit (FY2025) | Full year 2025 | ~$1.2B (includes ~$185M of new DPP revenues; excludes pending D.C. program) |
| Acute care revenue growth | FY2025 / intermediate term | 5%-7% (~6% midpoint); running in line |
| Behavioral pricing growth | Intermediate term | 4%-5% sustainable (Q2 at 4.2%) |
| Behavioral adjusted patient day growth target | Intermediate/long term | 2.5%-3% long-term target (remaining elusive; Q2 at 1.2%) |
| Cedar Hill EBITDA drag | Q2 + back half 2025 | $25M in Q2 plus another $25M in the back half |
| OB3 aggregate net benefit reduction | 2028 onset, ramping to 2032 | ~$360M-$400M by 2032 (~60% behavioral / 40% acute) |
| Share repurchase | Full year 2025 | Elevated above original range as free cash flow increases |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Adjusted EPS (Q2) | — | $5.35 per diluted share; reported net income $5.43 per share |
| Acute same-facility net revenues (Q2) | +5.7% | In line with guidance; pricing skewed by favorable payer mix (less Medicaid, more commercial/exchange) |
| Acute same-facility EBITDA (Q2) | +10% | Solid revenues plus effective expense control (other opex up 3.1%) |
| Acute same-facility adjusted admissions (Q2) | +2.0% | Volume growth partly offset by West Henderson cannibalization; surgical volumes down slightly |
| Behavioral same-facility net revenues (Q2, ex-Tennessee) | +5.4% | 4.2% revenue per adjusted day and 1.2% adjusted patient day growth |
| Behavioral revenue per adjusted day (Q2, ex-Tennessee) | +4.2% | Within the 4%-5% sustainable pricing range |
| Behavioral adjusted patient days (Q2) | +1.2% | Improved from Q1 but below target; outpatient growing faster than inpatient |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Outpatient behavioral strategy | Q1 discussion of outpatient focus; inpatient-centric history | Step-in freestanding model plus step-down; plans to open 10-15 low-capital outpatient facilities per year; Q2 outpatient outgrew inpatient | — |
| OB3 / DPP cliff | Legislation newly enacted | Worst-case ~$360M-$400M reduction by 2032 (60% behavioral / 40% acute); management expects mitigation and possible legislative tweaks | — |
| AI and technology | Early revenue-cycle experiments | Using AI for denial management/appeals countermeasures, ER coding, and AI-generated post-discharge follow-up calls; plus patient-rounding wearable tech | — |
| Behavioral volume struggle | Q1 volumes soft on staffing | Improved to 1.2% in Q2 but still below 2.5%-3% target; back-half projections trimmed; staffing and outpatient capture remain the levers | — |
| Cedar Hill ramp | — | Certification delay caused $25M Q2 drag and another $25M for the back half; ER demand encouraging; expected to ramp to divisional profitability by 2026 | — |
| Capital allocation | Original $600M-$700M buyback plan | Elevated buybacks as free cash flow rises; leverage continuing to decline; sub-2x leverage preserving flexibility | — |
Q&A Summary
How do you offset the ~$360M-$400M 2032 DPP headwind and what does it mean for core growth?
Reductions do not begin materially until 2028, giving time to shift behavioral program mix away from Medicaid-centric care and cut costs; management cited pandemic-era agility and expects the worst-case to improve via mitigation and possible legislative changes.
What is the split between behavioral inpatient and outpatient patient days and how will you grow outpatient?
Adjusted patient days grew faster than unadjusted, showing outpatient outgrew inpatient in Q2; growth comes from better capturing step-down patients and expanding step-in freestanding facilities, with insurers' rising behavioral spend concentrated in outpatient.
What is Cedar Hill's accreditation status and back-half guidance impact?
Medicare certification via Joint Commission survey was believed imminent; a $25M Q2 drag plus $25M back-half drag are embedded, with ramp to divisional profitability expected 12-18 months into 2026.
With state-directed payments and Cedar Hill aside, why is underlying EBITDA guidance roughly unchanged?
About $185M of new DPP revenues are offset by ~$50M of Cedar Hill drag plus a further reduction from trimmed back-half behavioral volume projections.
What is the pathway to grabbing more outpatient behavioral share?
Mostly low-capital (~$1M each) leased step-in facilities off-campus plus better step-down control; plans to open 10-15 such facilities per year, with therapist staffing the main constraint rather than capital.
How did acute volume trend across payer cohorts and will favorable mix persist?
Acute revenue grew 5.7% (in line with guidance), skewed toward pricing on a favorable payer mix of less Medicaid and more commercial/exchange volume; management expects extraordinary growth to keep moderating.
How is managed care disruption affecting rate discussions and labor?
Strong behavioral managed care increases continue due to bed scarcity; the main impact is a daily revenue-cycle slog against aggressive payer denials; wage inflation has decelerated and contract labor use is lower in both segments, though behavioral staffing remains tight in some markets.
Is 2.5%-3% behavioral volume still the right target given outpatient mix shift?
Yes over the long term; the target has been elusive because payers are shifting patients to outpatient and UHS has not captured its fair share, but focus and sequential Q1-to-Q2 improvement support reaching it.
How should we think about the ripple effects of 2027 Medicaid work requirements?
The disenrolled group (largely young, healthy males) are not heavy utilizers; acute Medicaid/uninsured mostly arrives via the ER with little UHS can do, while behavioral offers more optionality to target preferable patient groups.
What is causing behavioral weakness and what is different for 2026?
A mix of new capacity build-out, sharper discharge/referral focus, and recruitment/retention efforts; management is creating capacity it lacked and expects continued quarter-over-quarter improvement.
More on Universal Health Services Inc
Reported 2025-07-29 · figures from the Universal Health Services Inc Q2 2025 earnings call.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.